PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Within-Subject Active vs Placebo Topical Applications
Drug: Within-Subject Active vs. Placebo Topical Applications

First Posted Date: 2018-11-30

Last Posted Date: 2019-06-24

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT03760042

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy

Not Applicable

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Other: Visit frequency

First Posted Date: 2018-11-30

Last Posted Date: 2023-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 312

Registration Number: NCT03760029

Locations: 🇨🇳
Children's Hospital of Chongqing Medical University (Liangjiang Branch), Chongqing, Chongqing, China
🇨🇳
Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Huashan Hospital, Fudan University, Shanghai, China

and more 5 locations

Palatability (Taste) of Oral Formulations of Bosutinib

Phase 1

Completed

Conditions: CML

Interventions: Drug: bosutinib high flavour
Drug: Bosutinib Mannitol
Drug: 200 Mg capsules of bosutinib in Water solution
Drug: bosunitib sorbitol
Drug: bosutinib in mannitol low sweet
Drug: bosutinib in mannitol high sweet
Drug: bosutinib taste low flavour
Drug: Bosutinib capsules in low sweet
Drug: bosutinib capsules high sweet
Drug: bosutinib capsules low flavour
Drug: bosutinib capsules in applesauce
Drug: Bosutinib capsules in yogurt
Drug: bosutinib capsules high flavour
Drug: bosutinib capsules in water

First Posted Date: 2018-11-20

Last Posted Date: 2020-07-10

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03747679

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Dabigatran

First Posted Date: 2018-11-15

Last Posted Date: 2020-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03742336

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

PF-06651600 for the Treatment of Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600 Induction Dose
Drug: PF-06651600 Maintenance Dose #1
Drug: PF-06651600 Maintenance Dose #2
Drug: PF-06651600 Maintenance Dose #3
Drug: Placebo

First Posted Date: 2018-11-07

Last Posted Date: 2022-02-24

Lead Sponsor: Pfizer

Target Recruit Count: 718

Registration Number: NCT03732807

Locations: 🇺🇸
Mosaic Dermatology, Beverly Hills, California, United States
🇺🇸
Dermatology Specialists, Inc., Murrieta, California, United States
🇺🇸
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Irvine, California, United States

and more 150 locations

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2018-11-06

Last Posted Date: 2024-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 1590

Registration Number: NCT03732638

Locations: 🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States
🇺🇸
Oklahoma Headache Center, Norman, Oklahoma, United States
🇺🇸
Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States

and more 84 locations

A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta

Phase 4

Withdrawn

Conditions: Healthy

Interventions: Drug: Duloxetine Hydrochloride Capsules
Drug: Cymbalta Capsules

First Posted Date: 2018-11-02

Last Posted Date: 2019-10-04

Lead Sponsor: Pfizer

Registration Number: NCT03729284

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Phase 4

Completed

Conditions: Pharmacokinetics
Safety
ECG

Interventions: Drug: Gemtuzumab Ozogamicin

First Posted Date: 2018-11-01

Last Posted Date: 2022-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT03727750

Locations: 🇭🇺
Semmelweis Egyetem I.sz Belgyogyaszati Klinika, Hematologiai Osztaly, Budapest, Hungary
🇬🇧
The Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, Dorset, United Kingdom
🇺🇸
Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States

and more 21 locations

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: lorlatinib

First Posted Date: 2018-10-31

Last Posted Date: 2024-06-21

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT03726333

Locations: 🇺🇸
University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States

and more 7 locations

Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers

Phase 3

Terminated

Conditions: Pain

Interventions: Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet

First Posted Date: 2018-10-26

Last Posted Date: 2021-09-24

Lead Sponsor: Pfizer

Target Recruit Count: 613

Registration Number: NCT03722238

Locations: 🇺🇸
Mills Pharmacy at Bluff Park, Hoover, Alabama, United States
🇺🇸
ACACIA Apothecary and Wellness, Tucson, Arizona, United States
🇺🇸
Summerfield Pharmacy, Riverview, Florida, United States

and more 24 locations

Home Terms & Conditions Privacy Policy